Progress for development of prostate treatment, results from STHLM3 presented today
Helena Wensman comments the new KI study We see the results from the large STHLM3 study as very positive news, not only as development is progressing and treatment may improve, but also because it provides positive effects for companies that work within this area, including AroCell. STHLM3 study is based on a very large number of genetic markers which are associated with risk for prostate cancer. These genetic markers are then combined with detailed patient information to make the test more reliable, to elevate safety in diagnosis of suspected prostate cancer.